How Much Did Tensive Raise?
Funding & Key Investors

Tensive, a biomedical startup established in 2012, has secured $560K in total capital, with its most recent funding round bringing in $560K through a major strategic investment. This significant backing underscores the company's progress in developing innovative bioresorbable scaffolds for natural breast reconstruction and augmentation.

What is Tensive?

Tensive
ManufacturingMedical Devices & EquipmentBusiness Services

Founded in 2012, Tensive S.r.l. is a biomedical enterprise specializing in advanced biomaterials technology. The company's core focus is the development of innovative bioresorbable scaffolds designed for natural breast reconstruction and augmentation. Its flagship product, REGENERA, aims to significantly enhance the quality of life for breast cancer survivors by offering a safe and effective solution for breast restoration post-lumpectomy. Tensive is currently engaged in clinical investigations to advance its products toward market availability, targeting patients who have undergone breast surgery. The company's mission is to improve clinical outcomes and broaden accessibility for women globally through its cutting-edge biomaterials.

How much funding has Tensive raised?

Tensive has raised a total of $560K across 1 funding round:

2016

Private Equity

$560K

Private Equity (2016): $560K with participation from Unicredit and Invitalia Ventures

Key Investors in Tensive

Unicredit

Unicredit is a major European banking group, likely providing significant financial backing and strategic guidance to companies within its investment portfolio.

Invitalia Ventures

Invitalia Ventures is the venture capital arm of Italy's national development agency, focusing on financing innovative projects and businesses with high growth potential.

What's next for Tensive?

The substantial enterprise-level funding Tensive has garnered, particularly the recent strategic investment, positions the company for accelerated growth and market penetration. This capital infusion is expected to fuel further clinical investigations, scale manufacturing capabilities, and support the commercial launch of REGENERA. The company's trajectory suggests a strong emphasis on regulatory approvals and market adoption, aiming to establish itself as a leader in the reconstructive surgery and biomaterials sector. Future developments will likely involve expanding its product pipeline and forging strategic partnerships to enhance its global reach.

See full Tensive company page
See More Financial Insights
No matching results.
Refine your search.

Additional financial insights in the Manufacturing industry

ManufacturingPulp & PaperPlastic, Packaging & Containers
Food & BeverageManufacturingAgricultureAnimals & Livestock
Industrial Machinery & EquipmentManufacturingOther Rental Stores (Furniture, A/V, Construction & Industrial Equipment)Retail
ManufacturingTest & Measurement EquipmentBusiness ServicesSoftware Testing

Frequently Asked Questions Regarding Tensive Financial Insights

What are the most recent funding rounds that Tensive has completed, and what were the funding rounds?
Tensive has recently completed 1 funding rounds: Private Equity on May 20, 2016.
What is the total amount of funding Tensive has raised to date?
Tensive has raised a total of $560K in funding to date.
How many funding rounds has Tensive completed?
Tensive has completed 1 funding rounds.
How much funding did Tensive raise in its most recent funding round?
Tensive raised $560K in its most recent funding round.
Who are the lead investors in Tensive's latest funding round?
The lead investor in Tensive's latest funding round was Unicredit. To access investor data and explore similar companies, sign up for ZoomInfo.
Which was the largest funding round in Tensive's history?
The largest funding round in Tensive's history was $560K.
See more information about Tensive